Group 1: Resumption and Suspension of Trading - Zhongwei Electronics will have its actual controller changed to Fu Yingbo, and its stock will resume trading starting tomorrow [1] - Nandu Power is planning a change in control and will suspend trading from December 12 [1] Group 2: Capital Increase and Mergers & Acquisitions - Zhaoxin Co., Ltd. plans to acquire 70% of the equity of Youde New Energy, a leading company in the new energy operation and maintenance sector [2] - Chunguang Technology intends to raise no more than 776 million yuan through a private placement for projects including the construction of a new facility for producing 8 million clean electrical products annually in Suzhou and a production base in Vietnam [2] - New Xing Foundry's subsidiary Wuhu New Xing plans to acquire 100% of China Resources Steel for a transaction price of 1.244 billion yuan [2] Group 3: Share Transfer - Jintian Titanium Industry's shareholder, the National Industrial Investment Fund, intends to acquire 4.90% of the company's shares [3] - Longda Co., Ltd.'s shareholder, Guolian Investment, plans to transfer 5.00% of its shares through an agreement [4] - Tailong Pharmaceutical's shareholder, Zhengzhou Tairong Industrial Investment, intends to transfer 8.73% of its shares through an agreement [5] Group 4: External Investments and Daily Operations - Zhuhai Gree's subsidiary, Zhejiang Gree, is increasing its capital and introducing external investor Yufu Gaoqing Fund [6] - Innovent Biologics has received approval for its next-generation TRK inhibitor, Zoltriatinib (ICP-723), for treating adult and adolescent patients with NTRK fusion gene solid tumors [6] - Jifeng Technology plans to sign a cooperation framework agreement with Dongtai United Aircraft Technology for an amount not exceeding 100 million yuan [7] - Vanke A reported that as of October 31, the company and its subsidiaries have a guarantee balance of 84.476 billion yuan, with no overdue guarantee matters [8] - Yujing Co., Ltd. has signed a 202 million yuan equipment contract with an overseas photovoltaic company and a domestic enterprise [9] - Duofuduo plans to increase its capital by 1 billion yuan to its subsidiary Guangxi Ningfu [10]

财通证券股份有限公司 关于 河南太龙药业股份有限公司 详式权益变动报告书 之 财务顾问核查意见 财务顾问 二〇二五年十二月 1 声明 依据《中华人民共和国证券法》《上市公司收购管理办法》《公开发行证券的公 司信息披露内容与格式准则第15号—权益变动报告书》《公开发行证券的公司信息披 露内容与格式准则第16号—上市公司收购报告书》及相关法律、法规和规范性文件的 规定，财通证券股份有限公司（以下简称"本财务顾问"）按照行业公认的业务标 准、道德规范，本着诚实信用、勤勉尽责的精神，对本次权益变动的相关情况和资料 进行了核查，对信息披露义务人出具的《河南太龙药业股份有限公司详式权益变动报 告书》所披露的内容出具核查意见，以供投资者和有关各方参考。 为此，本财务顾问特作出以下声明： 一、本财务顾问已按照规定履行了尽职调查义务，对信息披露义务人披露的《河 南太龙药业股份有限公司详式权益变动报告书》进行了核查，确信披露文件内容与格 式符合规定，并有充分理由确信所发表的专业意见与信息披露义务人披露的文件内容 不存在实质性差异； 二、本财务顾问有充分理由确信本次权益变动符合相关法律、行政法规的规定， 有充分理由确信信息披露义务 ...

Core Viewpoint - Tailong Pharmaceutical (600222) is set to change ownership to Jiangxi State-owned Assets Supervision and Administration Commission, following a week-long suspension of trading, with significant market reactions observed upon resumption of trading [1] Group 1: Ownership Change - Tailong Pharmaceutical's controlling shareholder, Zhengzhou Tairong Industrial Investment Co., Ltd., has signed a share transfer agreement with Jiang Pharmaceutical Group Jiangxi Medical Holdings Co., Ltd. [1] - The agreement involves the transfer of 50.1 million shares, representing 8.73% of the total share capital, at a price of 11.043 yuan per share, which is nearly a 30% premium compared to the price before the suspension [1] - The total transaction value amounts to 553 million yuan [1] Group 2: Shareholding Structure - After the first delivery of 42.3 million shares, Jiang Pharmaceutical Holdings will directly hold 7.37% of the shares and, through a concerted action arrangement, will control a total of 14.37% of the shares [1] - The controlling shareholder will change from Zhengzhou High-tech Industrial Development Zone Management Committee to Jiangxi Provincial State-owned Assets Supervision and Administration Commission [1] Group 3: Corporate Actions - The company's board has approved a plan for a private placement to Jiang Pharmaceutical Holdings [1]

太龙药业(600222)今日下跌9.15%，全天换手率13.00%，成交额5.66亿元，振幅5.27%。龙虎榜数据显 示，机构净卖出740.08万元，营业部席位合计净卖出105.07万元。 上交所公开信息显示，当日该股因日跌幅偏离值达-8.91%上榜，机构专用席位净卖出740.08万元。 证券时报·数据宝统计显示，上榜的前五大买卖营业部合计成交8905.69万元，其中，买入成交额为 4030.27万元，卖出成交额为4875.42万元，合计净卖出845.16万元。 具体来看，今日上榜的营业部中，共有1家机构专用席位现身，即卖四，合计净卖出740.08万元。 资金流向方面，今日该股主力资金净流出5565.31万元，其中，特大单净流出3534.22万元，大单资金净 流出2031.09万元。近5日主力资金净流出2.46亿元。 10月30日公司发布的三季报数据显示，前三季度公司共实现营业收入11.87亿元，同比下降11.47%，实 现净利润2532.55万元，同比下降12.36%。（数据宝） 太龙药业12月10日交易公开信息 | 买/ | 会员营业部名称 | 买入金额（万 | 卖出金额（万 | | --- | --- ...

Core Viewpoint - The control change of Tailong Pharmaceutical to Jiangxi state-owned assets reflects the transformation anxiety of traditional Chinese medicine enterprises amid industry policy changes and intensified market competition, with the potential for state capital to provide crucial support for overcoming development bottlenecks [1][10]. Group 1: Control Change Details - Jiangxi state-owned Jiangyao Holdings will acquire control of Tailong Pharmaceutical through a combination of "share transfer + directed issuance," investing over 1 billion yuan [1][2]. - The share transfer involves Jiangyao Holdings purchasing 50.1 million shares (8.73% of total shares) at 11.043 yuan per share, totaling 553 million yuan, with the transfer occurring in two phases [2]. - To ensure a smooth transition of control, an agreement was signed for joint action, allowing Jiangyao Holdings to control 14.37% of shares during the transition period [2][3]. Group 2: Financial Performance - In the first three quarters of 2025, Tailong Pharmaceutical reported revenue of 1.187 billion yuan, a year-on-year decline of 11.47%, and a net profit of 25.33 million yuan, down 12.36% [4]. - The company faced significant pressure in 2025, with a net profit of only 1.53 million yuan in the first quarter, a drastic drop of 92.80% year-on-year [5]. - The pharmaceutical formulation segment, which has the highest gross margin, saw a revenue decline of 37.73% in the first three quarters of 2025, directly impacting overall profitability [5][6]. Group 3: Strategic Implications of State Capital Involvement - The entry of Jiangxi state capital is expected to provide multiple benefits, including optimization of the industrial chain layout, market channel expansion, and integration of research and development resources [7][8]. - Jiangyao Holdings aims to leverage its extensive channel resources in the pharmaceutical distribution sector to enhance Tailong Pharmaceutical's market penetration and alleviate pricing pressures [7][8]. - The 454 million yuan raised from the directed issuance will be used to improve cash flow and reduce financial costs, providing sufficient funding for operations and research [8]. Group 4: Industry Context and Future Outlook - The involvement of state capital in traditional Chinese medicine enterprises is becoming a significant trend, as local state-owned enterprises frequently invest in the pharmaceutical industry to help traditional companies overcome challenges and transform [10][11]. - The entry of state capital is reshaping the industry landscape, providing financial support and facilitating the concentration of resources towards stronger enterprises [11]. - However, the success of state capital involvement depends on effective management and integration, as past experiences show that not all state-controlled enterprises have improved performance [11].

资金流向方面，今日该股主力资金净流出1.91亿元，其中，特大单净流出1.04亿元，大单资金净流出 8637.32万元。近5日主力资金净流出1.91亿元。 10月30日公司发布的三季报数据显示，前三季度公司共实现营业收入11.87亿元，同比下降11.47%，实 现净利润2532.55万元，同比下降12.36%。（数据宝） 太龙药业12月9日交易公开信息 | 买/卖 | 会员营业部名称 | 买入金额（万元） | 卖出金额（万元） | | --- | --- | --- | --- | | 买一 | 国泰海通证券股份有限公司总部 | 1925.65 | | | 买二 | 国信证券股份有限公司浙江互联网分公司 | 1282.73 | | | 买三 | 东方财富证券股份有限公司拉萨东环路第二证券营业部 | 1257.13 | | | 买四 | 东方财富证券股份有限公司拉萨金融城南环路证券营业部 | 1048.06 | | | 买五 | 东方财富证券股份有限公司拉萨团结路第一证券营业部 | 935.16 | | | 卖一 | 粤开证券股份有限公司深圳深南大道证券营业部 | | 2569.81 | | 卖二 | 国泰海通证 ...

刚宣布拟易主的太龙药业(600222)今日复牌后股价却坐上"过山车"。 9日，以双黄连口服液出名的中药企业太龙药业以涨停价复牌，但很快该股股价直线跳水，迅速由红翻绿并于低位震荡。午后，太龙药业股价于盘中触及 跌停，上演"天地板"，最终收跌4.43%。 | स्त्रेष्ठव | 多日 1分 5分 15分 30分 ■ | F9 盘前盘后 叠加 九转 画线 工具 (2) >> | 太龙药业 1 立即 | 8.20 -0.38 -4.43% | 600222[太龙药业] 15:00 价 8.20 涨跌 -0.38(-4.43%) 均价 8.36 成交量 1.59万 成交... | 600222 交易 | | | | | | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | SSE CNY 15:00:01 闭市 查看L2全县 | 原ノ ● 十 | 详情 | -40.08% 委差 | -2 ...

作者 | 晓琳 编辑 | 郑瑶 医药行业国资入主整合浪潮，再添新案例。 01 协议转让+定增 江药控股拟入主太龙药业 12月8日，河南太龙药业股份有限公司（以下简称"太龙药业"）发布控股股东、实际控制人拟发生变更公告。公告称，江药集团江西医药控股有限公司 （以下简称"江药控股"）将成为公司新控股股东，实际控制人也将变更为江西省国有资产监督管理委员会。 据了解，本次江药控股通过 "协议转让+定增"方式入主，总交易额约10.07亿元。详情如下： 现控股股东泰容产投将持有的太龙药业5010万股股份（占公司当前总股本的8.73%）以 11.043元/股的价格转让给江药控股。本次股份转让分两次交割，第 一次交割4230股，第二次交割780万股，两次总价款约5.53亿元。 与此同时，为实现太龙药业控制权平稳过渡，泰容产投与江药控股签署了《一致行动协议》。在第一次股份交割完成之日起，江药控股通过直接持股加一 致行动控制的股份比例将达14.37%，以实现对太龙药业的实质控制。 除协议转让外，江药控股拟通过现金方式，认购太龙药业向特定对象发行的约7460.52万股股票（含本数）。本次发行价格为6.09元/股，不低于定价基准 日 ...

Economic Performance - In October 2025, Henan's industrial added value increased by 7.9%, outperforming the national average by 3.0 percentage points[21] - The province's social retail sales reached 2673.23 billion yuan, growing by 4.1% year-on-year, which is 1.2 percentage points higher than the national average[22] - Fixed asset investment in Henan rose by 4.5%, exceeding the national decline of 1.7%[23] Market Trends - In November 2025, the Henan Index fell by 1.47%, a smaller decline compared to the Shanghai Composite Index and the CSI 300 Index[48] - Year-to-date, the Henan Index has increased by 36.82%, consistently outperforming major benchmarks[48] Investment Landscape - As of November 2025, Henan's total market capitalization for A-shares was 19006.61 billion yuan, ranking 11th nationally and 2nd in Central China[62] - The province had 138 listed companies, with 113 A-shares and 31 H-shares, maintaining its 12th and 9th positions nationally[60] IPO and Financing Activity - No new IPOs were approved in Henan as of November 2025, with only one company completing equity financing totaling 1.15 million yuan in the first 11 months[40] - The province's credit bond issuance in November was 276.17 billion yuan, a decrease of 15.69% from the previous month[35]

Mergers and Acquisitions - China Metallurgical Group Corporation plans to sell assets worth 60.676 billion yuan to Minmetals Land and China Minmetals [1] - Shengda Resources intends to acquire 60% stake in Jinshi Mining for 500 million yuan [1] - Honghua Digital Science plans to acquire 49% stake in Shandong Yingkejie for 105 million yuan [1] - Weidi Co., Ltd. is set to acquire controlling stake in Jiangsu Jiuxing Precision Technology [1] Shareholding Changes - PIANO's controlling shareholder is planning a change in control, leading to stock suspension [1] - Tai Long Pharmaceutical's controlling shareholder will change to Jiangyao Holdings, with stock resuming trading [1] - ST Yishite's control will shift to Jingzhou State-owned Assets Supervision and Administration Commission [1] Buybacks and Reductions - Midea Group has completed its share buyback plan with a total amount reaching 10 billion yuan [1] - Helen Zhe plans to repurchase shares worth between 50 million to 100 million yuan [1] - Several companies, including Zhongfu Circuit and Keri International, are planning to reduce their shareholdings by up to 3% [1] Operational Data - Zhongtong Bus reported a sales volume of 1,133 units in November, marking a year-on-year increase of 39.53% [1] - Keming Foods' subsidiary saw a 110.77% year-on-year increase in pig sales revenue in November [2] - Yisheng Co., Ltd. reported a 28.43% decrease in sales revenue from white feather broiler chicks in November, totaling 215 million yuan [2] Major Investments - Cambridge Technology plans to invest 100 million USD in CIG USA to expand high-speed optical module production capacity in North America and Southeast Asia [2] - Zhejiang Rongtai intends to invest approximately 545 million yuan in Thailand for the production of 14,000 tons of mica paper and other products [2] - China Ocean Shipping Company plans to invest 258 million yuan in Shenshan Port Investment Company [2]